Company news
Newcelx Ltd. (NASDAQ:NCEL) news
Newcelx Ltd. news releases on 6ix. Latest, Sep 28, 2026: NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission…
Press releases & updates
NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
September 28, 2026
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
July 31, 2026
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
July 8, 2026
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
June 15, 2026
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
May 26, 2026
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
April 29, 2026
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
April 20, 2026
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
March 31, 2026
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
March 8, 2026
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
February 12, 2026
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
January 28, 2026
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
January 11, 2026
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
January 5, 2026
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
December 10, 2025
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
November 16, 2025
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
November 5, 2025
NewcelX CEO Issues Letter to Shareholders
November 3, 2025
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.
November 3, 2025
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
October 30, 2025